Pharmacological inhibition of DOT1L additionally upregulates the expression of natural killer group 2 D (NKG2D) ligands, in particular ULBP1, which correlates with increased natural killer (NK) cell-mediated eradication of ovarian cancer cells. The gene discussed is DOT1L; the disease is ovarian carcinoma.